Phase 1 Trial of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety and establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION537 when administered by intravenous infusion in patients with advanced solid tumors.